Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01960296 · ClinicalTrials.gov registry record · Phase 2
Does Continued Use of Clopidogrel Into Surgery Cause Increased Perioperative Bleeding?
A Phase 2 study, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT01960296 is a Phase 2 study that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 48 participants.
The verdict
NCT01960296, a Phase 2 study, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
Patients who on taking clopidogrel are randomized to either continue clopidogrel into general surgery or discontinue clopidogrel 7 days before surgery. All patients resume clopidogrel after surgery. The investigators track the development of bleeding complications that may develop within 90 days of the surgery. Patients are medically cleared to be in either arm of the study by their cardiologist and surgeon. There is currently no evidence to support for or against the use continuation or discontinuation of clopidogrel prior to general surgery.
Interventions
- DRUG Clopidogrel
- DRUG Discontinue Clopidogrel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2012-01 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01960296
The ClinicalTrials.gov registry entry for NCT01960296 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Clopidogrel is the first listed.
NCT01960296 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01960296 about?
NCT01960296 is a clinical study titled "Does Continued Use of Clopidogrel Into Surgery Cause Increased Perioperative Bleeding?". Patients who on taking clopidogrel are randomized to either continue clopidogrel into general surgery or discontinue clopidogrel 7 days before surgery. All patients resume clopidogrel after surgery. The investigators track the development of bleeding complications that may develop within 90 days of ...
What is the current status of trial NCT01960296?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2012-01. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01960296?
The interventions under investigation include: Clopidogrel (DRUG), Discontinue Clopidogrel (DRUG).
Who is sponsoring clinical trial NCT01960296?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.